• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hearing Disorders - Pipeline Review, H2 2012 Product Image

Hearing Disorders - Pipeline Review, H2 2012

  • Published: December 2012
  • 74 Pages
  • Global Markets Direct

FEATURED COMPANIES

  • Adherex Technologies Inc.
  • Fate Therapeutics, Inc.
  • GenVec, Inc.
  • Pfizer Inc.
  • Xigen SA
  • MORE

Hearing Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Hearing Disorders - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hearing Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hearing Disorders. Hearing Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hearing Disorders.
- A review of the Hearing Disorders products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Hearing Disorders Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Hearing Disorders 9
Hearing Disorders Therapeutics under Development by Companies 11
Hearing Disorders Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Hearing Disorders Therapeutics – Products under Development by Companies 18
Hearing Disorders Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Hearing Disorders Therapeutics Development 20
Adherex Technologies Inc. 20
GenVec, Inc. 21
Quark Pharmaceuticals, Inc. 22
Pfizer Inc. 23
Living Cell Technologies Limited 24
MedGenesis Therapeutix Inc. 25
Xigen SA 26
Fate Therapeutics, Inc. 27
Sound Pharmaceuticals, Inc. 28
Hearing Disorders – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
sodium thiosulfate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AHL - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AHLi-11 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Neuroprotection And Neural Regeneration Program - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
XG-102 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AMT-090 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(R)-Lipoic acid - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
prednisone - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
mecasermin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PF-04958242 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SPI-1005 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ebselen - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SPI-5557 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
dexamethasone acetate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TherAtoh - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NTCell - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
valganciclovir hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Hearing Restoration Program - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Hearing Disorders Therapeutics – Drug Profile Updates 59
Hearing Disorders Therapeutics – Discontinued Products 64
Hearing Disorders Therapeutics - Dormant Products 65
Hearing Disorders – Product Development Milestones 66
Featured News & Press Releases 66
Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 66
Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 67
Jan 04, 2012: Research Publication Shows AM-111's Otoprotective Effect In Cochlear Ischemia 67
Oct 07, 2011: Adherex Reports Meeting With FDA'S Pediatric Subcommittee Of Oncologic Drugs Advisory Committee On Development Of Sodium Thiosulfate Injection 67
Mar 04, 2011: Auris Medical's AM-111 Protects Against Hearing Loss From Cochlear Implant Electrode Insertion Trauma 68
Jan 17, 2011: Auris Medical Starts Enrolment In Second Cohort Of Phase IIb Study With AM-111 69
Jun 28, 2010: Fate Therapeutics Receives Red Herring's North America 100 Award For Advancing Stem Cell Technology And New Medicines 69
Feb 04, 2010: Fate Therapeutics Receives Allowance Of First U.S. Patent For Induced Pluripotent Stem Cell Technology 70
Dec 01, 2009: Fate Therapeutics' IPSC Technology Awarded Top Industry Honors For Small Molecule And Protein Reprogramming Breakthroughs 71
Nov 16, 2009: Fate Therapeutics Closes $30 Million Series B Financing 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products Under Development for Hearing Disorders, H2 2012 9
Products under Development for Hearing Disorders – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Adherex Technologies Inc., H2 2012 20
GenVec, Inc., H2 2012 21
Quark Pharmaceuticals, Inc., H2 2012 22
Pfizer Inc., H2 2012 23
Living Cell Technologies Limited, H2 2012 24
MedGenesis Therapeutix Inc., H2 2012 25
Xigen SA, H2 2012 26
Fate Therapeutics, Inc., H2 2012 27
Sound Pharmaceuticals, Inc., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Hearing Disorders Therapeutics – Drug Profile Updates 59
Hearing Disorders Therapeutics – Discontinued Products 64
Hearing Disorders Therapeutics – Dormant Products 65

List of Figures
Number of Products under Development for Hearing Disorders, H2 2012 9
Products under Development for Hearing Disorders – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

- Adherex Technologies Inc.
- GenVec, Inc.
- Quark Pharmaceuticals, Inc.
- Pfizer Inc.
- Living Cell Technologies Limited
- MedGenesis Therapeutix Inc.
- Xigen SA
- Fate Therapeutics, Inc.
- Sound Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos